Table 2.
Multivariable Cox proportional hazard model demonstrating the influence of preoperative PSA on the adjusted risk of cancer-specific mortality
| Covariates | 95% CI | P | |
|---|---|---|---|
| Year of diagnosis | 0.953 | 0.920 - 0.987 | 0.0074 |
| Age (years) | |||
| <45 (reference) | |||
| 45–54 | 0.736 | 0.387–1.402 | 0.3518 |
| 55–64 | 0.886 | 0.472–1.661 | 0.7049 |
| 65–74 | 1.066 | 0.567–2.004 | 0.8421 |
| 75–84 | 1.759 | 0.879–3.522 | 0.1107 |
| ≥85 | 6.924 | 1.505–31.85 | 0.0129 |
| Race | |||
| White (reference) | |||
| Black | 1.083 | 0.894–1.312 | 0.4177 |
| Asian or Pacific Islander | 0.649 | 0.459–0.918 | 0.0146 |
| American Indian | 0.201 | 0.050–0.804 | 0.0233 |
| Region | |||
| Midwest (reference) | |||
| Northeast | 1.036 | 0.806–1.333 | 0.7816 |
| South | 1.111 | 0.877–1.408 | 0.3838 |
| West | 1.013 | 0.823–1.247 | 0.8999 |
| PSA, (ng/ml) | |||
| < 4 (reference) | |||
| 4–10 | 0.803 | 0.659–0.978 | 0.0294 |
| >10 | 2.307 | 1.776–2.998 | <0.0001 |
| Clinical tumor stage | |||
| T1 (reference) | |||
| T2 | 1.459 | 1.275–1.669 | <0.0001 |
| T3 | 4.099 | 3.26–5.153 | <0.0001 |
| T4 | 8.066 | 4.614–14.102 | <0.0001 |
| Unknown | 1.844 | 0.76–4.472 | 0.1761 |
This analysis adjusted for year of diagnosis, patient demographics, and tumor stage.
CI, confidence interval; PSA, prostate-specific antigen.